Literature DB >> 14623949

Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.

L M Vilá1, G S Alarcón, G McGwin, A W Friedman, B A Baethge, H M Bastian, B J Fessler, J D Reveille.   

Abstract

OBJECTIVES: To compare the baseline clinical manifestations, immunological features, disease activity and damage accrual in systemic lupus erythematosus (SLE) patients from two US Hispanic subgroups.
METHODS: A total of 105 Hispanic SLE patients from Texas (a population of Mexican or Central American ancestry) and 81 from the island of Puerto Rico (all Puerto Ricans) participating in a longitudinal study of outcome were examined. The socio-economic/demographic, clinical and immunological variables were obtained at the time of enrollment (T(0)). Disease activity was determined with the Systemic Lupus Activity Measure (SLAM), and disease damage with the Systemic Lupus International Collaborating Clinics (SLICC) Damage Index (SDI). Disease activity was also determined at the time of diagnosis (T(D)).
RESULTS: At T(0) Hispanics from Texas were younger than those from Puerto Rico (33.1 +/- 12.0 vs 37.5 +/- 11.6 yr, P = 0.0125). Both groups were similar with regard to gender distribution (92.4 vs 95.1% females) and disease duration (1.4 +/- 1.4 vs 1.7 +/- 1.3 yr). Hispanics from Texas were more likely to have serositis (60.0 vs 8.6%, P < 0.0001), renal involvement (41.0 vs 13.6%, P < 0.0001), psychosis (5.7 vs 0.0%, P = 0.0365) and thrombocytopenia (21.0 vs 3.7%, P = 0.0006). On the other hand, Hispanics from Puerto Rico were more likely to have photosensitivity (81.5 vs 41.0%, P < 0.0001), malar rash (65.4 vs 45.7%, P = 0.0074) and discoid rash (13.6 vs 2.9%, P = 0.0060). At baseline, the presence of anti-dsDNA antibodies was higher in Hispanics from Texas (69.5% vs 46.9%, P = 0.0018) while anti-Ro antibodies were more frequent in Hispanics from Puerto Rico (24.7 vs 11.4%, P = 0.0175). Mean SLAM scores at T(D) (12.9 +/- 6.4 vs 9.1 +/- 4.6, P < 0.0001) and T(0) (10.9 +/- 6.3 vs 6.6 +/- 3.8, P < 0.0001) were significantly higher in Hispanics from Texas. Similarly, mean SDI scores at T(0) were higher in Hispanics from Texas (0.67 +/- 1.08 vs 0.26 +/- 0.54, P = 0.0026). By stepwise Poisson regression, SDI scores were associated with older age, disease activity and ethnicity (Hispanics from Texas).
CONCLUSIONS: Early in SLE, marked differences are observed between Hispanics from Texas and Puerto Rico. Higher disease activity, more major organ involvement, higher frequency of anti-dsDNA antibodies and more damage accrual occur in Hispanic lupus patients from Texas than in those from Puerto Rico.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623949     DOI: 10.1093/rheumatology/keh048

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  24 in total

1.  Suspects in the tale of lupus-associated thrombocytopenia.

Authors:  P D Ziakas; J G Routsias; S Giannouli; A Tasidou; A G Tzioufas; M Voulgarelis
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 2.  [Early diagnosis in patients with systemic lupus erythematosus (SLE)].

Authors:  M Gaubitz; H Schotte
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

3.  Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability.

Authors:  A M Bertoli; M Fernández; G S Alarcón; L M Vilá; J D Reveille
Journal:  Ann Rheum Dis       Date:  2006-06-30       Impact factor: 19.103

4.  Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose.

Authors:  Lesliane E Castro-Santana; Marilú Colón; María J Molina; Vanessa E Rodríguez; Angel M Mayor; Luis M Vilá
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

5.  Development and initial validation of a self-assessed lupus organ damage instrument.

Authors:  Karen H Costenbader; Munther Khamashta; Silvia Ruiz-Garcia; Maria Teresa Perez-Rodriguez; Michelle Petri; Jennifer Elliott; Susan Manzi; Elizabeth W Karlson; Tabitha Turner-Stokes; Bonnie Bermas; Jonathan Coblyn; Elena Massarotti; Peter Schur; Patricia Fraser; Iris Navarro; John G Hanly; Timothy S Shaver; Robert S Katz; Eliza Chakravarty; Paul R Fortin; Martha L Sanchez; Jigna Liu; Kaleb Michaud; Graciela S Alarcón; Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

6.  Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico.

Authors:  María J Molina; Angel M Mayor; Alejandro E Franco; Carlos A Morell; Miguel A López; Luis M Vilá
Journal:  J Clin Rheumatol       Date:  2007-08       Impact factor: 3.517

7.  Organ damage in high-risk patients with systemic and incomplete lupus syndromes.

Authors:  Nancy J Olsen; Maha Yousif; Azza Mutwally; Melinda Cory; Nada Elmagboul; David R Karp
Journal:  Rheumatol Int       Date:  2013-05-30       Impact factor: 2.631

8.  Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations.

Authors:  Elena Sánchez; Astrid Rasmussen; Laura Riba; Eduardo Acevedo-Vasquez; Jennifer A Kelly; Carl D Langefeld; Adrianne H Williams; Julie T Ziegler; Mary E Comeau; Miranda C Marion; Ignacio García-De La Torre; Marco A Maradiaga-Ceceña; Mario H Cardiel; Jorge A Esquivel-Valerio; Jacqueline Rodriguez-Amado; José Francisco Moctezuma; Pedro Miranda; Carlos E Perandones; Cecilia Castel; Hugo A Laborde; Paula Alba; Jorge L Musuruana; I Annelise Goecke; Juan-Manuel Anaya; Kenneth M Kaufman; Adam Adler; Stuart B Glenn; Elizabeth E Brown; Graciela S Alarcón; Robert P Kimberly; Jeffrey C Edberg; Luis M Vilá; Lindsey A Criswell; Gary S Gilkeson; Timothy B Niewold; Javier Martín; Timothy J Vyse; Susan A Boackle; Rosalind Ramsey-Goldman; R Hal Scofield; Michelle Petri; Joan T Merrill; John D Reveille; Betty P Tsao; Lorena Orozco; Vicente Baca; Kathy L Moser; Patrick M Gaffney; Judith A James; John B Harley; Teresa Tusié-Luna; Bernardo A Pons-Estel; Chaim O Jacob; Marta E Alarcón-Riquelme
Journal:  Arthritis Rheum       Date:  2012-11

9.  Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution.

Authors:  Paula I Burgos; Elizabeth L Perkins; Guillermo J Pons-Estel; Scott A Kendrick; Jigna M Liu; William T Kendrick; William J Cook; Bruce A Julian; Graciela S Alarcón; Clifton E Kew
Journal:  Arthritis Rheum       Date:  2009-09

10.  Impact of immigration on the clinical expression of systemic lupus erythematosus: a comparative study of Hispanic patients residing in the USA and Mexico.

Authors:  América G Uribe; Juanita Romero-Díaz; Mandar Apte; Mónica Fernández; Paula I Burgos; John D Reveille; Jorge Sánchez-Guerrero; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-08-28       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.